Wang YY - Search Results

1

[How to draft editorial explanation for transparent and concise guideline on clinical practice--Case analysis].

Liao X, Yu DD, Xie YM, Guo YB, Zhang XX, Fan CZ, Chen W, Jiang JJ, Wang YY. Liao X, et al. Among authors: wang yy. Zhongguo Zhong Yao Za Zhi. 2017 Dec;42(23):4520-4528. doi: 10.19540/j.cnki.cjcmm.20171012.007. Zhongguo Zhong Yao Za Zhi. 2017. PMID: 29376247 Chinese.

2

[Preliminary exploration on building a soft index dependent efficacy evaluation mode of Chinese medicine].

Xie YM, Wang YY, Piao HY. Xie YM, et al. Among authors: wang yy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Jun;27(6):560-4. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007. PMID: 17633376 Chinese.

3

[Brief talk on the problem and countermeasure in clinical trial design of acupuncture for treatment of stroke].

Zhi YJ, Xie YM, Zhao H, Wang YY. Zhi YJ, et al. Among authors: wang yy. Zhongguo Zhen Jiu. 2008 Nov;28(11):839-42. Zhongguo Zhen Jiu. 2008. PMID: 19055292 Chinese.

4

[Research on signal detection methods based on data mining in adverse drug reaction of shuanghuanglian injection].

Chen J, Wei Y, Sun J, Wang Y, Xie Y. Chen J, et al. Zhongguo Zhong Yao Za Zhi. 2010 Feb;35(3):308-12. doi: 10.4268/cjcmm20100312. Zhongguo Zhong Yao Za Zhi. 2010. PMID: 20422995 Chinese.

5

[Thought on several problems of clinical revaluation of post-marketing herb research].

He W, Xie Y, Wang Y. He W, et al. Zhongguo Zhong Yao Za Zhi. 2010 Jun;35(12):1641-3. Zhongguo Zhong Yao Za Zhi. 2010. PMID: 20815225 Chinese.

6

[Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].

He W, Xie Y, Wang Y. He W, et al. Zhongguo Zhong Yao Za Zhi. 2010 Jun;35(11):1498-500. Zhongguo Zhong Yao Za Zhi. 2010. PMID: 20822030 Chinese.

7

[Introduce the idea of comparative effectiveness research to clinical research of Chinese medicine].

Xie YM, Liao X, Wang YY. Xie YM, et al. Among authors: wang yy. Zhong Xi Yi Jie He Xue Bao. 2011 Aug;9(8):813-8. doi: 10.3736/jcim20110801. Zhong Xi Yi Jie He Xue Bao. 2011. PMID: 21849140 Chinese.

8

[Basic requirements on post-marketing clinical re-evaluation of chinese medicine and phase IV clinical trials].

Xie Y, Wang Y, Tian F, Wang Y. Xie Y, et al. Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2764-7. Zhongguo Zhong Yao Za Zhi. 2011. PMID: 22292359 Chinese.

9

[Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke].

Wei X, Ye X, Xie Y, Zou Y, Zhao X, Han J, Wang X, Ma Y, Bi Q, Xie Q, Zhao J, Cao X, Chen H, Wang S, Yan R, Han Z, Yi D, Wang Y. Wei X, et al. Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2789-92. Zhongguo Zhong Yao Za Zhi. 2011. PMID: 22292366 Clinical Trial. Chinese.

10

[Post-marketing re-evaluation of Kudiezi injection study on early treatment in patients with ischemic stroke].

Ye X, Wei X, Xie Y, Zou Y, Zhao X, Han J, Wang X, Ma Y, Bi Q, Xie Q, Zhao J, Cao X, Chen H, Wang S, Yan R, Han Z, Yi D, Wang Y. Ye X, et al. Zhongguo Zhong Yao Za Zhi. 2011 Oct;36(20):2793-5. Zhongguo Zhong Yao Za Zhi. 2011. PMID: 22292367 Clinical Trial. Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,151 results

Search Page

Filters